Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33 results about "Polymyositis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.
Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
Owner:ARENA PHARMA
Microarray-ELISA detecting reagent kit for detecting autoimmunity disease relevant antibody spectrum
InactiveCN101063680AImprove throughputHigh parallelMaterial analysisDiffuse sclerodermaAutoimmune responses
This invention relates to one anti-extracting nuclear antigen spectrum array to ELISA test agent case for selecting for systematic lupus erythematosus, mixed connective tissue disease, Sjogren syndrome, systemic scleroderma, polymyositis and atrophic arthritis system self immune property antigen ENA spectrum micro array to enzyme immune agent case.
Owner:BEIJING BGI GBI BIOTECH +4
Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.
Owner:ARENA PHARMA
Application of norisoboldine in preparing medicament for treating autoimmune disease
InactiveCN101375850AOrganic active ingredientsImmunological disordersImmunologic disordersUlcerative colitis
The invention relates to the medicine filed, in particular to a medicinal purpose of norisoboldine. The medicinal purpose is characterized in that the norisoboldine can be used in the application of preparing drugs for the treatment of autoimmune diseases. The autoimmune diseases are: rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, multiple sclerosis, type-I diabetes, psoriasis, ulcerative colitis, Sjogren syndrome, scleroderma, polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, autoimmune hemolytic anemia and other diseases.
Owner:CHINA PHARM UNIV
Treating microvasculature diseases with acetyl cholinesterase inhibitors
There is disclosed a method of treating various diseases caused by micro-vasculature circulation problems, including, but not limited to, vascular insufficiency, phantom pain, diabetic neuropathy, neuropathic pain, autoimmune / inflammatory diseases (e.g., multiple sclerosis, Parkinson's disease, Crohn's Disease, lupus, rheumatoid arthritis, polymyalgia rheumatica, polymyositis, dermatomyositis, sarcoidosis), urinary retention, lymphoedema, and chronic renal insufficiency. Specifically, there is disclosed a treatment providing an effective amount of an acetyl cholinesterase inhibitor compound (or combination of compounds) to treat one or a plurality of microvasculature diseases.
Owner:WILLS STEPHEN
Colloidal gold chromatography anti-Jo-1 antibody detection test paper and preparation method thereof
ActiveCN102621308AHigh detection sensitivityReduce manufacturing costMaterial analysisJo-1 antibodyCellulose
The invention discloses a colloidal gold chromatography anti-Jo-1 antibody detection test paper and a preparation method thereof. The colloidal gold chromatography anti-Jo-1 antibody detection test paper comprises a sample pad, a combination pad, a cellulose nitrate coated film and a water absorption pad, and the sample pad, the combination pad, the cellulose nitrate coated film and the water absorption pad are pasted on a base plate sequentially from one side of the base plate to the other side of the base plate, wherein the combination pad is coated with a gold-labeled antibody a and a gold-labeled antibody b; and the cellulose nitrate coated film is provided with a detection line and a quality control line, the detection line is coated with a Jo-1 antigen protein, and the quality control line is coated with a gold-labeled antibody c. By adopting indirect immunoassay to introduce the Jo-1 antigen protein in the invention to carry out process optimization on the combination pad and the sample pad, so high sensitivity, high specificity and high accuracy detection performances of the anti-Jo-1 antibody are realized, and a reference basis is provided for the auxiliary diagnosis of dermatomyositis / polymyositis.
Owner:SHANGHAI KEXIN BIOTECH
Glucocorticoid synergist
InactiveCN101084910AImprove biological effectReduce dosageOrganic active ingredientsAntipyreticDiseaseDexamethasone
The invention relates to medical technology field, discloses a glucocorticoid synergist, and is characterized in adopting total ginsenoside as synergist. Its proportions are respectively as following: total ginsenoside 200mg-1200mg and dexamethasone 0.75-187.5mg; total ginsenoside 200mg-1200mg and betamethason 0.75-187.5mg; total ginsenoside 200-1200mg, and prednisone 5-1250mg, total ginsenoside 200-1200mg, and precortisyl 5-1250mg; total ginsenoside 200mg-1200mg, and urbason 4-1000mg; total ginsenoside 200-1200mg, and cortisone 25-6250mg; and total ginsenoside 200-1200mg, and hydrocortisone 20-5000mg.Total ginsenoside as glucocorticoid synergist can be used in the treatment of diseases requiring long term or a large amount of glucocorticoid such as systemic lupus erythematosus, nephrotic syndrome, polymyositis, and rheumatoid arthritis.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Treatment of diseases caused by viral infection
InactiveUS20060018876A1Eliminate and inhibit proliferationPrevent and treat diseaseBiocidePeptide/protein ingredientsSIDS - Sudden infant death syndromeMyocarditis
A method of prophylactic and / or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and / or treat the disease in the mammal. A composition for treatment of a mammal for a disease caused by Ljungan virus infection including an antiviral compound, antiserum, and an interferon. A method of treatment of a mammal for a disease caused by a Ljungan virus infection.
Owner:APODEMUS
Treatment of diseases caused by viral infection
InactiveUS7442380B2Eliminate and inhibit proliferationPrevent and treat diseaseBiocidePeptide/protein ingredientsSIDS - Sudden infant death syndromeTherapeutic treatment
A method of prophylactic and / or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and / or treat the disease in the mammal. A composition for treatment of a mammal for a disease caused by Ljungan virus infection including an antiviral compound, antiserum, and an interferon. A method of treatment of a mammal for a disease caused by a Ljungan virus infection.
Owner:APODEMUS
Urea and thiourea compounds and compositions for cholesterol management and related uses
InactiveUS20050192347A1Increase productionUrea derivatives preparationBiocideBile productionDiabetic retinopathy
The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, enhancing bile production, enhancing reverse lipid transport, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, modulating C reactive protein, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), a thrombotic disorder, gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), arthritis (e.g., rheumatoid arthritis, osteoarthritis), autoimmune disease (e.g., systemic lupus erythematosus), scleroderma, ankylosing spondylitis, gout and pseudogout, muscle pain: polymyositis / polymyalgia rheumatica / fibrositis; infection and arthritis, juvenile rheumatoid arthritis, tendonitis, bursitis and other soft tissue rheumatism. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS
Use of geldanamycin and related compounds for treatment of fibrogenic disorders
InactiveUS6887853B2Effective treatmentBiocidePhosphorous compound active ingredientsGeldanamycinHsp Inhibitor
A method for prophylaxis or treatment of a mammal, particularly human, at risk for a fibrogenic disorder is disclosed. The compositions and methods of the invention are directed both to treatments for existing fibrogenic disorders and prevention thereof. Such disorders include, but are not limited to, connective tissue diseases, such as scleroderma (or systemic sclerosis), polymyositis, systemic lupus erythematosis and rheumatoid arthristis, and other fibrotic disorders, including liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis. A therapeutic composition according to the invention includes, as a therapeutic agent, an inhibitor of a collagen promoter in a pharmaceutically acceptable inert carrier vehicle, preferably for local, and particularly topical, application. Exemplary inhibitors include those that interfere with heat shock protein 90 (Hsp 90) chaperone function, e.g., the specific inhibitor geldanamycin or other known Hsp90 inhibitors such as macbecin I and II, herbimycin, radcicol and novobiocin.
Owner:TRUSTEES OF BOSTON UNIV
Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
The present invention relates to fatty acid analogues of the general formula R1-[xi-CH2]n—COOR2 and in particular to a method of treating inflammatory disorder selected from the group consisting of rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and polymyositis; comprising administering to a mammal in need thereof, an effective amount of tetradecylthioaceticacid or tetradecylselenoacetic acid; or a pharmaceutically acceptable salt thereof.
Owner:BERGEN TEKNOLOGIOVERFORING AS
Kit and detection method for determining anti-Jo-1 antibody
The invention relates to a kit for determining an anti-Jo-1 antibody. The kit comprises a first reagent, wherein the first reagent comprises a mixture coupled with biotin. The mixture comprises a Jo-1antigen and a tRNA. According to the kit and the detection method for determining anti-Jo-1 antibody, the invention has the advantages of good stability, high sensitivity, good repeatability and thelike; a detection system can realize random sample loading, freely combination and continuously detecting, and the detection time is greatly reduced that 120 tests can be completed within 1 hour; andoperations are simple and convenient, a full automatic detection is truly realized, and the result deviation caused by the operations is avoided. Compared with a traditional method, the detection result of the invention is consistent in conformity, and the detection rate of a Jo-1 antibody positive in dermatomyositis / polymyositis is increased to 35%-40%, furthermore the positive signal value is increased by 10-20%.
Owner:SUZHOU HAOOUBO BIOPHARML
Diagnosis of gluten sensitive enteropathy and other autoimmunopathies
InactiveUS7781169B1Increased riskReduce the overall heightDisease diagnosisBiological testingInsulin dependentRheumatism
Method for diagnosis of autoimmune diseases of the GSE-type or associated with gluten sensitive enteropathy comprising taking a sample and testing the sample for antibodies against human tissue transglutaminase, tissue-specific transglutaminases, or other transglutaminases. It was found that autoimmune diseases other than celiac disease can be diagnosed and distinguished in this way, notably, dermatitis herpetiformis Duhring, Crohn's disease, Addison's disease, AI hemolytic anemia, AI thrombocytopenic purpura, AI thyroid diseases, atrophic gastritis—pernicious anemia, IgA nephropathy or IgA glomerulonephritis, myasthenia gravis, partial lipodystrophy, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, recurrent pericarditis, relapsing polychondritis, rheumatoid arthritis, rheumatism, sarcoidosis, Sjögren's syndrome, SLE, splenic atrophy, type I (insulin-dependent) diabetes mellitus, diabetes mellitus of other types, ulcerative colitis, vasculitis (both systemic and cutaneous), vitiligo as well as autoimmune diseases associated with infertility, increased risk of abortion, or reduced fetal growth.
Owner:PAULSSON MATS +5
Traditional Chinese medicine composition for treating polymyositis and preparation method and application of traditional Chinese medicine composition for treating polymyositis
InactiveCN105687365ASimple prescriptionLow cost of treatmentAnthropod material medical ingredientsAntipyreticSide effectCurative effect
The invention discloses a traditional Chinese medicine composition for treating polymyositis. The traditional Chinese medicine composition for treating polymyositis comprises, by weight, 18-20 parts of Rhizoma Coptidis, 6-9 parts of Rhizoma Menispermi, 12-15 parts of Cortex Fissistigmatis Bracteolati Radicis, 18-20 parts of herb of laciniate blumea, 11-13 parts of Herba Epimedii, 4-6 parts of Radix Paeoniae Rubra, 5-6 parts of Herba Ephedrae, 9-12 parts of Feculae Bombycis and 3-5 parts of Gomphrena globosa L.. The invention further provides a preparation method of the traditional Chinese medicine composition for treating polymyositis. The traditional Chinese medicine composition for treating polymyositis is simple in formula, remarkably effective in treatment of polymyositis by being as high as 98.5% in total effective rate and less prone to causing relapse after cure, and is lower in treatment cost and less in toxic or side effect than glucocorticoid, thereby being beneficial to health of patients.
Owner:王维娜
Detection kit for antinuclear antibody repertoires
The invention discloses a detection kit for antinuclear antibody repertoires, and belongs to the technical field of detection kits. The detection kit comprises a composite micro bead suspension, a fluorescence indicator and a sample diluent, wherein a plurality of micro beads are contained in the composite micro bead suspension; a part of micro beads are coated with different types of autologous antigens respectively, a part of micro beads are coated with antigens prepared from HEP-2 cells, a part of micro beads are coated with antigens capable of detecting non-specific antibodies in patient samples, and the remaining micro beads are four types of standard control micro beads; the fluorescence indicator is phycoerythrin labeled goat-anti-human IgG (specific gamma chain); the sample diluentis a scrubbing solution. The detection for a plurality of autologous antibodies can be performed for one patient sample inside the same hole, so that auxiliary diagnosis is provided for various systemic autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, scleroderma, polymyositis, mixed connective tissue disease (MCTD), drug-induced SLE and sjogren syndrome.
Owner:宙斯生命科技(常州)有限公司
Application of vanillic acid glucoside derivative in treatment of systemic autoimmune disease
ActiveCN102949404APrevent proliferationLower levelOrganic active ingredientsSenses disorderVanillic acidS syndrome
The invention discloses application of a vanillic acid glucoside derivative as shown in formula (I) in treatment of a systemic autoimmune disease. Preferably, the systemic autoimmune disease can be selected from systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjogren's syndrome, and polymyositis.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Drug for reducing side effects of leflunomide
InactiveCN107158107AReduce the side effects of LeformideAntipyreticAnalgesicsSide effectClinical trial
The invention discloses a drug for reducing side effects of leflunomide and belongs to the technical field of drugs. The drug for reducing the side effects of the leflunomide is prepared from leflunomide and auxiliary materials of a biologic preparation. A clinical test proves that the problem that the leflunomide easily generates the side effect during clinical treatment of polymyositis can be effectively solved.
Owner:张凤霞
Mi-2 recombinant antigen as well as preparation method and application thereof
ActiveCN111849930AOvercome difficultyOvercome yieldAntibody mimetics/scaffoldsMicroorganism based processesAntiendomysial antibodiesVirology
The invention relates to the technical field of biology, and particularly provides a Mi-2 recombinant antigen as well as a preparation method and application thereof. The Mi-2 recombinant antigen comprises at least one sequences representing by SEQ ID NO.1, SEQ ID NO.5 or SEQ ID NO.7, and does not contain sequences representing by SEQ ID NO.2 and / or SEQ ID NO.6. The Mi-2 recombinant antigen improves the sensitivity and specificity of Mi-2 antibody detection, is used for Mi-2 antibody detection or polymyositis diagnosis, can greatly improve the accuracy, and provides a new technical support forproduction and application.
Owner:ZHUHAI LIVZON DIAGNOSTICS
Boosting the effect of methotrexate through the combined use with lipophilic statins
The invention relates to the use of an inhibitor of the dihydrofolate reductase enzyme selected from the group that consists of methotrexate, trimetrexate and pemetrexed; or a pharmaceutically acceptable salt thereof, for the preparation of a drug for the treatment or prevention of recurrences of a disease selected from the group that consists of cancer, psoriasis, psoriatic arthritis, juvenile polyarticular arthritis, rheumatoid arthritis, Crohn's disease, polymyositis, dermatomyositis and sarcoidosis, wherein said treatment or prevention includes administering to a patient, simultaneously, separately or sequentially, a lipophilic statin and the inhibitor of the dihydrofolate reductase enzyme. The invention also relates to a pharmaceutical composition which includes the inhibitor of the dihydrofolate reductase enzyme and the lipophilic statin together with pharmaceutically acceptable carriers and / or vehicles.
Owner:DALANA3
Application of norisoboldine in preparing medicament for treating autoimmune disease
InactiveCN101375850BOrganic active ingredientsImmunological disordersImmunologic disordersUlcerative colitis
The invention relates to the medicine filed, in particular to a medicinal purpose of norisoboldine. The medicinal purpose is characterized in that the norisoboldine can be used in the application of preparing drugs for the treatment of autoimmune diseases. The autoimmune diseases are: rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, multiple sclerosis, type-I diabetes, psoriasis, ulcerative colitis, Sjogren syndrome, scleroderma, polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, autoimmune hemolytic anemia and other diseases.
Owner:CHINA PHARM UNIV
Application of lncRNA AK124826 and related molecules thereof in diagnosis of polymyositis/dermatomyositis
InactiveCN111617096AEfficient activationRaise the ratioOrganic active ingredientsMicrobiological testing/measurementPharmaceutical drugVirus
The invention discloses application of a medicine for preventing or treating polymyositis / dermatomyositis or diagnosis reagent or test kit. The invention also discloses application of the lncRNA AK124826 slow virus overexpression vector in the preparation of drugs for preventing or treating polymyositis / dermatomyositis or a diagnosis reagent or a test kit. The invention further discloses application of a RNAi interference vector of the lncRNA AK124826 in preparation of the drugs for preventing or treating polymyositis / dermatomyositis or the diagnosis reagent or the test kit.
Owner:常熟市第二人民医院
Aminoalcohol derivative, pharmaceutical composition and use thereof
ActiveCN109206383AEasy to prepareMild reaction conditionsOrganic active ingredientsNervous disorderUlcerative colitisArthritis
Owner:FORELAND PHARM CO LTD
Amino alcohol derivative, pharmaceutical composition and application thereof
ActiveUS20210347745A1Efficient targetingSimple processOrganic active ingredientsNervous disorderUlcerative colitisImmunologic Competence
The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.
Owner:FORELAND PHARM CO LTD
Colloidal gold chromatography anti-Jo-1 antibody detection test paper and preparation method thereof
ActiveCN102621308BHigh detection sensitivityReduce manufacturing costMaterial analysisJo-1 antibodyCellulose
Owner:SHANGHAI KEXIN BIOTECH
Anti-LAP monoclonal antibody as well as antigen binding fragment and application thereof
ActiveCN113402607AEnhance immune responseThere is a huge clinical needDigestive systemImmunoglobulins against animals/humansAntigenAutoimmune condition
The invention relates to the field of biological medicine, and provides an anti-LAP monoclonal antibody or an antigen binding fragment thereof, and the anti-LAP monoclonal antibody comprises heavy chain variable regions HCDR1, HCDR2 and HCDR3 and light chain variable regions LCDR1, LCDR2 and LCDR3. The anti-LAP monoclonal antibody provided by the invention inhibits release of TGF beta1 from the source, deletes inhibitory T cells and improves tumor immune response, can be combined with various immunotherapy drugs for application, can be expanded to more types of cancers, autoimmune diseases and fibrosis diseases, and has huge clinical requirements and huge market potential; the cancers are selected from non-small cell lung cancer, colorectal cancer, pancreatic cancer, kidney cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma or glioma; the fibrosis diseases comprise pulmonary fibrosis or hepatic fibrosis; and the autoimmune diseases are selected from systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis or xerosis.
Owner:BEIJING DONGFANG BIOTECH
Traditional Chinese medicine preparation for treating polymyositis
The invention discloses a traditional Chinese medicine preparation for treating polymyositis and belongs to the technical field of traditional Chinese medicine. From the perspective of traditional Chinese medicine, it is considered that polymyositis is caused by the fact that deficiency of the spleen and stomach and interior accumulation of dampness and turbidity lead to heat and toxicity with time resulting in stagnation, and damp stagnation and toxic stagnation fight with each other and fully fill the skin. Japanese Premna Herb, Hedyotis Hispida, Passiflora Cochinchinensis, Berchemia Floribunda Root, Cynanchum mooreanum, Semen Litchi, Allium Paepalanthoides, Geranium Eriostemum, Millettia Reticulata, Ophiopogon Latifolius, Large-leaved Uncaria Root, Parochetus Communis and Vitis Balanseana are decocted with water into decoction. Clinical test in our hospital shows that various indexes such as muscle strength and muscle tenderness of the treatment group are obviously better than those of the control group, particularly, no side effect is caused on the treatment group, and recurrence rate is low.
Owner:蒋金霞
Boosting the effect of methotrexate through the combined use with lipophilic statins
InactiveUS20160175310A1Less side effectsBiocideAntipyreticDihydrofolate reductase inhibitorSarcoidosis
The invention relates to the use of an inhibitor of the dihydrofolate reductase enzyme selected from the group that consists of methotrexate, trimetrexate and pemetrexed; or a pharmaceutically acceptable salt thereof, for the preparation of a drug for the treatment or prevention of recurrences of a disease selected from the group that consists of cancer, psoriasis, psoriatic arthritis, juvenile polyarticular arthritis, rheumatoid arthritis, Crohn's disease, polymyositis, dermatomyositis and sarcoidosis, wherein said treatment or prevention includes administering to a patient, simultaneously, separately or sequentially, a lipophilic statin and the inhibitor of the dihydrofolate reductase enzyme. The invention also relates to a pharmaceutical composition which includes the inhibitor of the dihydrofolate reductase enzyme and the lipophilic statin together with pharmaceutically acceptable carriers and / or vehicles.
Owner:DALANA3
A kind of anti-lap monoclonal antibody, its antigen-binding fragment and application thereof
ActiveCN113402607BEnhance immune responseThere is a huge clinical needDigestive systemImmunoglobulins against animals/humansAntigenAutoimmune condition
The present invention relates to the field of biomedicine, and provides an anti-LAP monoclonal antibody or an antigen-binding fragment thereof, including heavy chain variable regions HCDR1, HCDR2, HCDR3 and light chain variable regions LCDR1, LCDR2, LCDR3. The anti-LAP monoclonal antibody provided by the present invention inhibits the release of TGFβ1 from the source, deletes suppressive T cells, improves tumor immune response, can be used in combination with various immunotherapy drugs, and can be extended to more types of cancer and autoimmune diseases And fibrotic diseases, with huge clinical needs and huge market potential; cancers are selected from non-small cell lung cancer, colorectal cancer, pancreatic cancer, kidney cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma or glioma; Fibrotic diseases include pulmonary fibrosis or liver fibrosis; autoimmune diseases are selected from systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis or Sjogren's disease.
Owner:BEIJING DONGFANG BIOTECH
A kit and detection method for measuring anti-JO-1 antibody
Owner:SUZHOU HAOOUBO BIOPHARML
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com